BioMarin Pharmaceutical controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile5 entries
2019
Kuvan post-trial access criticism
UK reporting described patients who had received Kuvan during a trial but later lacked access to continued treatment. The matter drew criticism from NHS representatives and a parliamentarian and was framed by critics as a pricing and patient-access issue.
2019
Belgian Vimizim supply litigation
After reimbursement discussions failed, BioMarin stopped free Vimizim supply to a child with Morquio syndrome. A Belgian court issued a preliminary injunction requiring continued supply while the dispute proceeded.
2015
Expanded-access dispute involving a German child
BioMarin faced criticism over the reported refusal to supply an investigational medicine to a German child with a brain disorder who was not enrolled in the relevant trial.
2013
BMN 673 expanded-access dispute
BioMarin declined to provide investigational PARP inhibitor BMN 673 to ovarian-cancer patient Andrea Sloan outside the clinical-trial framework, citing safety concerns. The case became prominent in debates over compassionate access to experimental drugs.
2010
Firdapse pricing controversy
BioMarin’s licensed Firdapse product was criticized after its European price was reported to be substantially higher than that of an earlier unlicensed 3,4-diaminopyridine treatment. BioMarin responded that licensing introduced formal quality controls and regulatory surveillance.